nodes	percent_of_prediction	percent_of_DWPC	metapath
Flecainide—CYP2C9—Gefitinib—lung cancer	0.0818	0.172	CbGbCtD
Flecainide—CYP2C9—Teniposide—lung cancer	0.0793	0.167	CbGbCtD
Flecainide—CYP2D6—Gefitinib—lung cancer	0.0748	0.157	CbGbCtD
Flecainide—CYP2D6—Vinorelbine—lung cancer	0.0576	0.121	CbGbCtD
Flecainide—CYP2C9—Paclitaxel—lung cancer	0.0443	0.0932	CbGbCtD
Flecainide—CYP2D6—Erlotinib—lung cancer	0.0442	0.0931	CbGbCtD
Flecainide—CYP2C9—Cisplatin—lung cancer	0.0356	0.075	CbGbCtD
Flecainide—CYP2D6—Vinblastine—lung cancer	0.0355	0.0748	CbGbCtD
Flecainide—CYP2D6—Doxorubicin—lung cancer	0.0218	0.0459	CbGbCtD
Flecainide—Mefloquine—ABCB1—lung cancer	0.00231	1	CrCbGaD
Flecainide—Vomiting—Vinorelbine—lung cancer	0.000234	0.00056	CcSEcCtD
Flecainide—Body temperature increased—Gemcitabine—lung cancer	0.000234	0.000559	CcSEcCtD
Flecainide—Renal failure—Methotrexate—lung cancer	0.000233	0.000558	CcSEcCtD
Flecainide—Rash—Vinorelbine—lung cancer	0.000232	0.000555	CcSEcCtD
Flecainide—Dermatitis—Vinorelbine—lung cancer	0.000232	0.000555	CcSEcCtD
Flecainide—Hypotension—Paclitaxel—lung cancer	0.000232	0.000554	CcSEcCtD
Flecainide—Headache—Vinorelbine—lung cancer	0.000231	0.000552	CcSEcCtD
Flecainide—Syncope—Docetaxel—lung cancer	0.000231	0.000552	CcSEcCtD
Flecainide—Leukopenia—Docetaxel—lung cancer	0.00023	0.000551	CcSEcCtD
Flecainide—Palpitations—Docetaxel—lung cancer	0.000227	0.000544	CcSEcCtD
Flecainide—Feeling abnormal—Cisplatin—lung cancer	0.000227	0.000544	CcSEcCtD
Flecainide—Paraesthesia—Etoposide—lung cancer	0.000227	0.000543	CcSEcCtD
Flecainide—Haematuria—Methotrexate—lung cancer	0.000226	0.000541	CcSEcCtD
Flecainide—Loss of consciousness—Docetaxel—lung cancer	0.000226	0.000541	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000226	0.00054	CcSEcCtD
Flecainide—Dyspnoea—Etoposide—lung cancer	0.000225	0.000539	CcSEcCtD
Flecainide—Somnolence—Etoposide—lung cancer	0.000225	0.000537	CcSEcCtD
Flecainide—Cough—Docetaxel—lung cancer	0.000225	0.000537	CcSEcCtD
Flecainide—Angina pectoris—Doxorubicin—lung cancer	0.000225	0.000537	CcSEcCtD
Flecainide—Insomnia—Paclitaxel—lung cancer	0.000224	0.000536	CcSEcCtD
Flecainide—Convulsion—Docetaxel—lung cancer	0.000223	0.000533	CcSEcCtD
Flecainide—Paraesthesia—Paclitaxel—lung cancer	0.000223	0.000532	CcSEcCtD
Flecainide—Hypertension—Docetaxel—lung cancer	0.000222	0.000531	CcSEcCtD
Flecainide—Agranulocytosis—Methotrexate—lung cancer	0.000222	0.00053	CcSEcCtD
Flecainide—Dyspnoea—Paclitaxel—lung cancer	0.000221	0.000528	CcSEcCtD
Flecainide—Somnolence—Paclitaxel—lung cancer	0.00022	0.000527	CcSEcCtD
Flecainide—Decreased appetite—Etoposide—lung cancer	0.00022	0.000525	CcSEcCtD
Flecainide—Myalgia—Docetaxel—lung cancer	0.000219	0.000524	CcSEcCtD
Flecainide—Arthralgia—Docetaxel—lung cancer	0.000219	0.000524	CcSEcCtD
Flecainide—Chest pain—Docetaxel—lung cancer	0.000219	0.000524	CcSEcCtD
Flecainide—Nausea—Vinorelbine—lung cancer	0.000219	0.000523	CcSEcCtD
Flecainide—Gastrointestinal disorder—Etoposide—lung cancer	0.000218	0.000522	CcSEcCtD
Flecainide—Dyspepsia—Paclitaxel—lung cancer	0.000218	0.000522	CcSEcCtD
Flecainide—Body temperature increased—Cisplatin—lung cancer	0.000218	0.000521	CcSEcCtD
Flecainide—Asthenia—Irinotecan—lung cancer	0.000218	0.000521	CcSEcCtD
Flecainide—Fatigue—Etoposide—lung cancer	0.000218	0.000521	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000218	0.00052	CcSEcCtD
Flecainide—Constipation—Etoposide—lung cancer	0.000216	0.000517	CcSEcCtD
Flecainide—Pain—Etoposide—lung cancer	0.000216	0.000517	CcSEcCtD
Flecainide—Dysuria—Doxorubicin—lung cancer	0.000216	0.000515	CcSEcCtD
Flecainide—Decreased appetite—Paclitaxel—lung cancer	0.000215	0.000515	CcSEcCtD
Flecainide—Dry mouth—Docetaxel—lung cancer	0.000214	0.000512	CcSEcCtD
Flecainide—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000214	0.000512	CcSEcCtD
Flecainide—Fatigue—Paclitaxel—lung cancer	0.000214	0.000511	CcSEcCtD
Flecainide—Asthenia—Gemcitabine—lung cancer	0.000212	0.000508	CcSEcCtD
Flecainide—Pain—Paclitaxel—lung cancer	0.000212	0.000507	CcSEcCtD
Flecainide—Constipation—Paclitaxel—lung cancer	0.000212	0.000507	CcSEcCtD
Flecainide—Confusional state—Docetaxel—lung cancer	0.000212	0.000506	CcSEcCtD
Flecainide—Photosensitivity reaction—Doxorubicin—lung cancer	0.00021	0.000503	CcSEcCtD
Flecainide—Oedema—Docetaxel—lung cancer	0.00021	0.000502	CcSEcCtD
Flecainide—Pruritus—Gemcitabine—lung cancer	0.000209	0.000501	CcSEcCtD
Flecainide—Feeling abnormal—Etoposide—lung cancer	0.000208	0.000498	CcSEcCtD
Flecainide—Hyperglycaemia—Doxorubicin—lung cancer	0.000208	0.000497	CcSEcCtD
Flecainide—Diarrhoea—Irinotecan—lung cancer	0.000208	0.000497	CcSEcCtD
Flecainide—Pneumonia—Doxorubicin—lung cancer	0.000207	0.000494	CcSEcCtD
Flecainide—Gastrointestinal pain—Etoposide—lung cancer	0.000207	0.000494	CcSEcCtD
Flecainide—Shock—Docetaxel—lung cancer	0.000207	0.000494	CcSEcCtD
Flecainide—Nervous system disorder—Docetaxel—lung cancer	0.000206	0.000492	CcSEcCtD
Flecainide—Thrombocytopenia—Docetaxel—lung cancer	0.000206	0.000492	CcSEcCtD
Flecainide—Visual impairment—Methotrexate—lung cancer	0.000205	0.000491	CcSEcCtD
Flecainide—Tachycardia—Docetaxel—lung cancer	0.000205	0.00049	CcSEcCtD
Flecainide—Feeling abnormal—Paclitaxel—lung cancer	0.000204	0.000488	CcSEcCtD
Flecainide—Skin disorder—Docetaxel—lung cancer	0.000204	0.000488	CcSEcCtD
Flecainide—Gastrointestinal pain—Paclitaxel—lung cancer	0.000203	0.000484	CcSEcCtD
Flecainide—Diarrhoea—Gemcitabine—lung cancer	0.000203	0.000484	CcSEcCtD
Flecainide—Renal failure—Doxorubicin—lung cancer	0.000202	0.000483	CcSEcCtD
Flecainide—Neuropathy peripheral—Doxorubicin—lung cancer	0.000201	0.000482	CcSEcCtD
Flecainide—Dizziness—Irinotecan—lung cancer	0.000201	0.00048	CcSEcCtD
Flecainide—Urticaria—Etoposide—lung cancer	0.000201	0.00048	CcSEcCtD
Flecainide—Jaundice—Doxorubicin—lung cancer	0.0002	0.000479	CcSEcCtD
Flecainide—Anorexia—Docetaxel—lung cancer	0.0002	0.000479	CcSEcCtD
Flecainide—Body temperature increased—Etoposide—lung cancer	0.0002	0.000478	CcSEcCtD
Flecainide—Abdominal pain—Etoposide—lung cancer	0.0002	0.000478	CcSEcCtD
Flecainide—Eye disorder—Methotrexate—lung cancer	0.000199	0.000476	CcSEcCtD
Flecainide—Tinnitus—Methotrexate—lung cancer	0.000199	0.000475	CcSEcCtD
Flecainide—Asthenia—Cisplatin—lung cancer	0.000198	0.000473	CcSEcCtD
Flecainide—Urticaria—Paclitaxel—lung cancer	0.000197	0.000471	CcSEcCtD
Flecainide—Hypotension—Docetaxel—lung cancer	0.000196	0.000469	CcSEcCtD
Flecainide—Haematuria—Doxorubicin—lung cancer	0.000196	0.000469	CcSEcCtD
Flecainide—Abdominal pain—Paclitaxel—lung cancer	0.000196	0.000468	CcSEcCtD
Flecainide—Body temperature increased—Paclitaxel—lung cancer	0.000196	0.000468	CcSEcCtD
Flecainide—Vomiting—Irinotecan—lung cancer	0.000193	0.000462	CcSEcCtD
Flecainide—Immune system disorder—Methotrexate—lung cancer	0.000192	0.00046	CcSEcCtD
Flecainide—Agranulocytosis—Doxorubicin—lung cancer	0.000192	0.000459	CcSEcCtD
Flecainide—Rash—Irinotecan—lung cancer	0.000192	0.000458	CcSEcCtD
Flecainide—Dermatitis—Irinotecan—lung cancer	0.000191	0.000458	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000191	0.000458	CcSEcCtD
Flecainide—Headache—Irinotecan—lung cancer	0.00019	0.000455	CcSEcCtD
Flecainide—Insomnia—Docetaxel—lung cancer	0.00019	0.000454	CcSEcCtD
Flecainide—Diarrhoea—Cisplatin—lung cancer	0.000189	0.000451	CcSEcCtD
Flecainide—Paraesthesia—Docetaxel—lung cancer	0.000189	0.000451	CcSEcCtD
Flecainide—Alopecia—Methotrexate—lung cancer	0.000188	0.00045	CcSEcCtD
Flecainide—Vomiting—Gemcitabine—lung cancer	0.000188	0.00045	CcSEcCtD
Flecainide—Bradycardia—Doxorubicin—lung cancer	0.000188	0.000449	CcSEcCtD
Flecainide—Dyspnoea—Docetaxel—lung cancer	0.000187	0.000448	CcSEcCtD
Flecainide—Somnolence—Docetaxel—lung cancer	0.000187	0.000446	CcSEcCtD
Flecainide—Rash—Gemcitabine—lung cancer	0.000187	0.000446	CcSEcCtD
Flecainide—Dermatitis—Gemcitabine—lung cancer	0.000186	0.000446	CcSEcCtD
Flecainide—Headache—Gemcitabine—lung cancer	0.000185	0.000443	CcSEcCtD
Flecainide—Dyspepsia—Docetaxel—lung cancer	0.000185	0.000442	CcSEcCtD
Flecainide—Hypoaesthesia—Doxorubicin—lung cancer	0.000184	0.000439	CcSEcCtD
Flecainide—Decreased appetite—Docetaxel—lung cancer	0.000183	0.000437	CcSEcCtD
Flecainide—Dysgeusia—Methotrexate—lung cancer	0.000182	0.000434	CcSEcCtD
Flecainide—Gastrointestinal disorder—Docetaxel—lung cancer	0.000181	0.000434	CcSEcCtD
Flecainide—Asthenia—Etoposide—lung cancer	0.000181	0.000434	CcSEcCtD
Flecainide—Fatigue—Docetaxel—lung cancer	0.000181	0.000433	CcSEcCtD
Flecainide—Nausea—Irinotecan—lung cancer	0.00018	0.000432	CcSEcCtD
Flecainide—Pain—Docetaxel—lung cancer	0.00018	0.000429	CcSEcCtD
Flecainide—Constipation—Docetaxel—lung cancer	0.00018	0.000429	CcSEcCtD
Flecainide—SCN4A—Axon guidance—IL6R—lung cancer	0.000179	0.00171	CbGpPWpGaD
Flecainide—Pruritus—Etoposide—lung cancer	0.000179	0.000428	CcSEcCtD
Flecainide—Visual impairment—Doxorubicin—lung cancer	0.000178	0.000425	CcSEcCtD
Flecainide—Asthenia—Paclitaxel—lung cancer	0.000178	0.000425	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—AKR1C1—lung cancer	0.000176	0.00168	CbGpPWpGaD
Flecainide—Nausea—Gemcitabine—lung cancer	0.000176	0.00042	CcSEcCtD
Flecainide—Vomiting—Cisplatin—lung cancer	0.000175	0.000419	CcSEcCtD
Flecainide—Pruritus—Paclitaxel—lung cancer	0.000175	0.000419	CcSEcCtD
Flecainide—Vision blurred—Methotrexate—lung cancer	0.000175	0.000418	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—AKR1C1—lung cancer	0.000174	0.00167	CbGpPWpGaD
Flecainide—Rash—Cisplatin—lung cancer	0.000174	0.000416	CcSEcCtD
Flecainide—Dermatitis—Cisplatin—lung cancer	0.000174	0.000416	CcSEcCtD
Flecainide—Feeling abnormal—Docetaxel—lung cancer	0.000173	0.000414	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—UGT1A1—lung cancer	0.000173	0.00166	CbGpPWpGaD
Flecainide—Diarrhoea—Etoposide—lung cancer	0.000173	0.000413	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CXCL8—lung cancer	0.000173	0.00165	CbGpPWpGaD
Flecainide—Eye disorder—Doxorubicin—lung cancer	0.000172	0.000412	CcSEcCtD
Flecainide—Ill-defined disorder—Methotrexate—lung cancer	0.000172	0.000411	CcSEcCtD
Flecainide—Tinnitus—Doxorubicin—lung cancer	0.000172	0.000411	CcSEcCtD
Flecainide—Gastrointestinal pain—Docetaxel—lung cancer	0.000172	0.000411	CcSEcCtD
Flecainide—CYP2C9—Biological oxidations—UGT1A1—lung cancer	0.000172	0.00164	CbGpPWpGaD
Flecainide—Flushing—Doxorubicin—lung cancer	0.000171	0.000409	CcSEcCtD
Flecainide—SCN4A—Axon guidance—MMP2—lung cancer	0.000171	0.00164	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—UGT1A1—lung cancer	0.000171	0.00164	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—MAP2K1—lung cancer	0.00017	0.00163	CbGpPWpGaD
Flecainide—Diarrhoea—Paclitaxel—lung cancer	0.00017	0.000405	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—UGT1A1—lung cancer	0.000169	0.00162	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—COL4A3BP—lung cancer	0.000169	0.00162	CbGpPWpGaD
Flecainide—Malaise—Methotrexate—lung cancer	0.000167	0.0004	CcSEcCtD
Flecainide—Dizziness—Etoposide—lung cancer	0.000167	0.0004	CcSEcCtD
Flecainide—Immune system disorder—Doxorubicin—lung cancer	0.000167	0.000398	CcSEcCtD
Flecainide—Vertigo—Methotrexate—lung cancer	0.000167	0.000398	CcSEcCtD
Flecainide—Abdominal pain—Docetaxel—lung cancer	0.000166	0.000397	CcSEcCtD
Flecainide—Body temperature increased—Docetaxel—lung cancer	0.000166	0.000397	CcSEcCtD
Flecainide—Leukopenia—Methotrexate—lung cancer	0.000166	0.000397	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CASP3—lung cancer	0.000165	0.00158	CbGpPWpGaD
Flecainide—Dizziness—Paclitaxel—lung cancer	0.000164	0.000392	CcSEcCtD
Flecainide—Nausea—Cisplatin—lung cancer	0.000164	0.000392	CcSEcCtD
Flecainide—Alopecia—Doxorubicin—lung cancer	0.000163	0.00039	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000162	0.00155	CbGpPWpGaD
Flecainide—Cough—Methotrexate—lung cancer	0.000162	0.000387	CcSEcCtD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000161	0.00154	CbGpPWpGaD
Flecainide—Convulsion—Methotrexate—lung cancer	0.000161	0.000384	CcSEcCtD
Flecainide—Vomiting—Etoposide—lung cancer	0.000161	0.000384	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—JUN—lung cancer	0.00016	0.00154	CbGpPWpGaD
Flecainide—Rash—Etoposide—lung cancer	0.000159	0.000381	CcSEcCtD
Flecainide—Dermatitis—Etoposide—lung cancer	0.000159	0.000381	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—FGFR1—lung cancer	0.000158	0.00152	CbGpPWpGaD
Flecainide—Headache—Etoposide—lung cancer	0.000158	0.000379	CcSEcCtD
Flecainide—Flatulence—Doxorubicin—lung cancer	0.000158	0.000378	CcSEcCtD
Flecainide—Myalgia—Methotrexate—lung cancer	0.000158	0.000378	CcSEcCtD
Flecainide—Chest pain—Methotrexate—lung cancer	0.000158	0.000378	CcSEcCtD
Flecainide—Arthralgia—Methotrexate—lung cancer	0.000158	0.000378	CcSEcCtD
Flecainide—Tension—Doxorubicin—lung cancer	0.000158	0.000377	CcSEcCtD
Flecainide—Vomiting—Paclitaxel—lung cancer	0.000158	0.000377	CcSEcCtD
Flecainide—Dysgeusia—Doxorubicin—lung cancer	0.000157	0.000376	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000157	0.000375	CcSEcCtD
Flecainide—Rash—Paclitaxel—lung cancer	0.000156	0.000374	CcSEcCtD
Flecainide—Dermatitis—Paclitaxel—lung cancer	0.000156	0.000373	CcSEcCtD
Flecainide—Discomfort—Methotrexate—lung cancer	0.000156	0.000373	CcSEcCtD
Flecainide—Nervousness—Doxorubicin—lung cancer	0.000156	0.000373	CcSEcCtD
Flecainide—Headache—Paclitaxel—lung cancer	0.000155	0.000371	CcSEcCtD
Flecainide—Confusional state—Methotrexate—lung cancer	0.000153	0.000365	CcSEcCtD
Flecainide—Vision blurred—Doxorubicin—lung cancer	0.000151	0.000362	CcSEcCtD
Flecainide—SCN4A—Axon guidance—RAF1—lung cancer	0.000151	0.00145	CbGpPWpGaD
Flecainide—Asthenia—Docetaxel—lung cancer	0.000151	0.00036	CcSEcCtD
Flecainide—SCN5A—Axon guidance—FGFR1—lung cancer	0.000151	0.00144	CbGpPWpGaD
Flecainide—Nausea—Etoposide—lung cancer	0.00015	0.000359	CcSEcCtD
Flecainide—SCN4A—Axon guidance—ERBB2—lung cancer	0.00015	0.00143	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KDR—lung cancer	0.000149	0.00143	CbGpPWpGaD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000149	0.00143	CbGpPWpGaD
Flecainide—Ill-defined disorder—Doxorubicin—lung cancer	0.000149	0.000356	CcSEcCtD
Flecainide—Pruritus—Docetaxel—lung cancer	0.000149	0.000355	CcSEcCtD
Flecainide—Nervous system disorder—Methotrexate—lung cancer	0.000148	0.000355	CcSEcCtD
Flecainide—Thrombocytopenia—Methotrexate—lung cancer	0.000148	0.000354	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—EP300—lung cancer	0.000148	0.00142	CbGpPWpGaD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000148	0.00142	CbGpPWpGaD
Flecainide—Nausea—Paclitaxel—lung cancer	0.000147	0.000352	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—HPGDS—lung cancer	0.000147	0.00141	CbGpPWpGaD
Flecainide—Skin disorder—Methotrexate—lung cancer	0.000147	0.000352	CcSEcCtD
Flecainide—Hyperhidrosis—Methotrexate—lung cancer	0.000146	0.00035	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—MET—lung cancer	0.000146	0.0014	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—HPGDS—lung cancer	0.000146	0.0014	CbGpPWpGaD
Flecainide—Malaise—Doxorubicin—lung cancer	0.000145	0.000346	CcSEcCtD
Flecainide—Vertigo—Doxorubicin—lung cancer	0.000144	0.000345	CcSEcCtD
Flecainide—Anorexia—Methotrexate—lung cancer	0.000144	0.000345	CcSEcCtD
Flecainide—Syncope—Doxorubicin—lung cancer	0.000144	0.000344	CcSEcCtD
Flecainide—Leukopenia—Doxorubicin—lung cancer	0.000144	0.000344	CcSEcCtD
Flecainide—Diarrhoea—Docetaxel—lung cancer	0.000144	0.000344	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—GSTT1—lung cancer	0.000143	0.00137	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—FOXO3—lung cancer	0.000142	0.00136	CbGpPWpGaD
Flecainide—Palpitations—Doxorubicin—lung cancer	0.000142	0.000339	CcSEcCtD
Flecainide—SCN5A—Axon guidance—KDR—lung cancer	0.000142	0.00136	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTT1—lung cancer	0.000141	0.00136	CbGpPWpGaD
Flecainide—Hypotension—Methotrexate—lung cancer	0.000141	0.000338	CcSEcCtD
Flecainide—Loss of consciousness—Doxorubicin—lung cancer	0.000141	0.000338	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—GCLC—lung cancer	0.000141	0.00135	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP2A6—lung cancer	0.000141	0.00135	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—VEGFA—lung cancer	0.00014	0.00134	CbGpPWpGaD
Flecainide—Cough—Doxorubicin—lung cancer	0.00014	0.000335	CcSEcCtD
Flecainide—CYP2C9—Biological oxidations—CYP2A6—lung cancer	0.00014	0.00134	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GCLC—lung cancer	0.00014	0.00134	CbGpPWpGaD
Flecainide—Convulsion—Doxorubicin—lung cancer	0.000139	0.000333	CcSEcCtD
Flecainide—Dizziness—Docetaxel—lung cancer	0.000139	0.000332	CcSEcCtD
Flecainide—SCN5A—Axon guidance—MET—lung cancer	0.000139	0.00133	CbGpPWpGaD
Flecainide—Hypertension—Doxorubicin—lung cancer	0.000139	0.000332	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000138	0.00033	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—ITGB1—lung cancer	0.000137	0.00131	CbGpPWpGaD
Flecainide—Insomnia—Methotrexate—lung cancer	0.000137	0.000327	CcSEcCtD
Flecainide—Arthralgia—Doxorubicin—lung cancer	0.000137	0.000327	CcSEcCtD
Flecainide—Chest pain—Doxorubicin—lung cancer	0.000137	0.000327	CcSEcCtD
Flecainide—Myalgia—Doxorubicin—lung cancer	0.000137	0.000327	CcSEcCtD
Flecainide—CYP2C9—Arachidonic acid metabolism—PTGS2—lung cancer	0.000137	0.00131	CbGpPWpGaD
Flecainide—Anxiety—Doxorubicin—lung cancer	0.000136	0.000326	CcSEcCtD
Flecainide—Paraesthesia—Methotrexate—lung cancer	0.000136	0.000325	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000136	0.000325	CcSEcCtD
Flecainide—Discomfort—Doxorubicin—lung cancer	0.000135	0.000323	CcSEcCtD
Flecainide—Dyspnoea—Methotrexate—lung cancer	0.000135	0.000323	CcSEcCtD
Flecainide—Somnolence—Methotrexate—lung cancer	0.000135	0.000322	CcSEcCtD
Flecainide—Dry mouth—Doxorubicin—lung cancer	0.000134	0.00032	CcSEcCtD
Flecainide—Vomiting—Docetaxel—lung cancer	0.000134	0.000319	CcSEcCtD
Flecainide—Dyspepsia—Methotrexate—lung cancer	0.000133	0.000319	CcSEcCtD
Flecainide—Rash—Docetaxel—lung cancer	0.000132	0.000317	CcSEcCtD
Flecainide—Dermatitis—Docetaxel—lung cancer	0.000132	0.000316	CcSEcCtD
Flecainide—Confusional state—Doxorubicin—lung cancer	0.000132	0.000316	CcSEcCtD
Flecainide—Decreased appetite—Methotrexate—lung cancer	0.000132	0.000315	CcSEcCtD
Flecainide—Headache—Docetaxel—lung cancer	0.000132	0.000315	CcSEcCtD
Flecainide—Oedema—Doxorubicin—lung cancer	0.000131	0.000313	CcSEcCtD
Flecainide—Gastrointestinal disorder—Methotrexate—lung cancer	0.000131	0.000312	CcSEcCtD
Flecainide—Fatigue—Methotrexate—lung cancer	0.000131	0.000312	CcSEcCtD
Flecainide—Pain—Methotrexate—lung cancer	0.000129	0.00031	CcSEcCtD
Flecainide—Shock—Doxorubicin—lung cancer	0.000129	0.000308	CcSEcCtD
Flecainide—Nervous system disorder—Doxorubicin—lung cancer	0.000129	0.000307	CcSEcCtD
Flecainide—Thrombocytopenia—Doxorubicin—lung cancer	0.000128	0.000307	CcSEcCtD
Flecainide—SCN4A—Axon guidance—MMP9—lung cancer	0.000128	0.00123	CbGpPWpGaD
Flecainide—Tachycardia—Doxorubicin—lung cancer	0.000128	0.000306	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	0.000128	0.00123	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—IL6R—lung cancer	0.000128	0.00122	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CREBBP—lung cancer	0.000127	0.00122	CbGpPWpGaD
Flecainide—Skin disorder—Doxorubicin—lung cancer	0.000127	0.000304	CcSEcCtD
Flecainide—Hyperhidrosis—Doxorubicin—lung cancer	0.000127	0.000303	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—HES1—lung cancer	0.000126	0.00121	CbGpPWpGaD
Flecainide—Anorexia—Doxorubicin—lung cancer	0.000125	0.000299	CcSEcCtD
Flecainide—Nausea—Docetaxel—lung cancer	0.000125	0.000298	CcSEcCtD
Flecainide—Feeling abnormal—Methotrexate—lung cancer	0.000125	0.000298	CcSEcCtD
Flecainide—Gastrointestinal pain—Methotrexate—lung cancer	0.000124	0.000296	CcSEcCtD
Flecainide—Hypotension—Doxorubicin—lung cancer	0.000122	0.000293	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—MMP2—lung cancer	0.000122	0.00117	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MAP2K1—lung cancer	0.000122	0.00117	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—IL6R—lung cancer	0.000121	0.00116	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—lung cancer	0.000121	0.00116	CbGpPWpGaD
Flecainide—Urticaria—Methotrexate—lung cancer	0.00012	0.000288	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—CYP2E1—lung cancer	0.00012	0.00115	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—lung cancer	0.00012	0.00115	CbGpPWpGaD
Flecainide—Abdominal pain—Methotrexate—lung cancer	0.00012	0.000286	CcSEcCtD
Flecainide—Body temperature increased—Methotrexate—lung cancer	0.00012	0.000286	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000119	0.000286	CcSEcCtD
Flecainide—CYP2C9—Biological oxidations—CYP2E1—lung cancer	0.000119	0.00114	CbGpPWpGaD
Flecainide—Insomnia—Doxorubicin—lung cancer	0.000119	0.000283	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—CYP2E1—lung cancer	0.000118	0.00113	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—SRC—lung cancer	0.000118	0.00113	CbGpPWpGaD
Flecainide—Paraesthesia—Doxorubicin—lung cancer	0.000118	0.000281	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—CYP2E1—lung cancer	0.000117	0.00112	CbGpPWpGaD
Flecainide—Dyspnoea—Doxorubicin—lung cancer	0.000117	0.000279	CcSEcCtD
Flecainide—Somnolence—Doxorubicin—lung cancer	0.000117	0.000279	CcSEcCtD
Flecainide—SCN5A—Axon guidance—MMP2—lung cancer	0.000116	0.00111	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MAP2K1—lung cancer	0.000116	0.00111	CbGpPWpGaD
Flecainide—Dyspepsia—Doxorubicin—lung cancer	0.000115	0.000276	CcSEcCtD
Flecainide—SCN4A—Axon guidance—VEGFA—lung cancer	0.000115	0.0011	CbGpPWpGaD
Flecainide—Decreased appetite—Doxorubicin—lung cancer	0.000114	0.000272	CcSEcCtD
Flecainide—SCN4A—Axon guidance—NRAS—lung cancer	0.000114	0.00109	CbGpPWpGaD
Flecainide—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000113	0.000271	CcSEcCtD
Flecainide—Fatigue—Doxorubicin—lung cancer	0.000113	0.00027	CcSEcCtD
Flecainide—Constipation—Doxorubicin—lung cancer	0.000112	0.000268	CcSEcCtD
Flecainide—Pain—Doxorubicin—lung cancer	0.000112	0.000268	CcSEcCtD
Flecainide—SCN4A—Axon guidance—MAPK3—lung cancer	0.000109	0.00104	CbGpPWpGaD
Flecainide—Asthenia—Methotrexate—lung cancer	0.000109	0.00026	CcSEcCtD
Flecainide—Feeling abnormal—Doxorubicin—lung cancer	0.000108	0.000258	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—RAF1—lung cancer	0.000108	0.00103	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—FGFR1—lung cancer	0.000107	0.00103	CbGpPWpGaD
Flecainide—Gastrointestinal pain—Doxorubicin—lung cancer	0.000107	0.000256	CcSEcCtD
Flecainide—Pruritus—Methotrexate—lung cancer	0.000107	0.000256	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—ERBB2—lung cancer	0.000107	0.00102	CbGpPWpGaD
Flecainide—Urticaria—Doxorubicin—lung cancer	0.000104	0.000249	CcSEcCtD
Flecainide—SCN4A—Axon guidance—EGFR—lung cancer	0.000104	0.000993	CbGpPWpGaD
Flecainide—Body temperature increased—Doxorubicin—lung cancer	0.000104	0.000248	CcSEcCtD
Flecainide—Abdominal pain—Doxorubicin—lung cancer	0.000104	0.000248	CcSEcCtD
Flecainide—Diarrhoea—Methotrexate—lung cancer	0.000104	0.000248	CcSEcCtD
Flecainide—SCN5A—Axon guidance—RAF1—lung cancer	0.000103	0.000982	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—ERBB2—lung cancer	0.000101	0.000972	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KDR—lung cancer	0.000101	0.000969	CbGpPWpGaD
Flecainide—Dizziness—Methotrexate—lung cancer	0.0001	0.000239	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	9.95e-05	0.000953	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MET—lung cancer	9.9e-05	0.000949	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTP1—lung cancer	9.89e-05	0.000948	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTP1—lung cancer	9.81e-05	0.00094	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—KRAS—lung cancer	9.8e-05	0.000938	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTP1—lung cancer	9.76e-05	0.000935	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—IL6—lung cancer	9.69e-05	0.000929	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTP1—lung cancer	9.67e-05	0.000927	CbGpPWpGaD
Flecainide—Vomiting—Methotrexate—lung cancer	9.63e-05	0.00023	CcSEcCtD
Flecainide—Rash—Methotrexate—lung cancer	9.55e-05	0.000228	CcSEcCtD
Flecainide—Dermatitis—Methotrexate—lung cancer	9.54e-05	0.000228	CcSEcCtD
Flecainide—Headache—Methotrexate—lung cancer	9.48e-05	0.000227	CcSEcCtD
Flecainide—Asthenia—Doxorubicin—lung cancer	9.41e-05	0.000225	CcSEcCtD
Flecainide—Pruritus—Doxorubicin—lung cancer	9.27e-05	0.000222	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—MMP9—lung cancer	9.16e-05	0.000877	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTM1—lung cancer	9.09e-05	0.000871	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTM1—lung cancer	9.01e-05	0.000863	CbGpPWpGaD
Flecainide—Nausea—Methotrexate—lung cancer	8.99e-05	0.000215	CcSEcCtD
Flecainide—Diarrhoea—Doxorubicin—lung cancer	8.97e-05	0.000214	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—GSTM1—lung cancer	8.97e-05	0.000859	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTM1—lung cancer	8.89e-05	0.000852	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MMP9—lung cancer	8.7e-05	0.000833	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—EP300—lung cancer	8.68e-05	0.000832	CbGpPWpGaD
Flecainide—Dizziness—Doxorubicin—lung cancer	8.67e-05	0.000207	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—IL6R—lung cancer	8.65e-05	0.000829	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CREBBP—lung cancer	8.64e-05	0.000828	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP1A1—lung cancer	8.62e-05	0.000826	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP1A1—lung cancer	8.54e-05	0.000819	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—CYP1A1—lung cancer	8.5e-05	0.000814	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—SRC—lung cancer	8.44e-05	0.000809	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—CYP1A1—lung cancer	8.43e-05	0.000807	CbGpPWpGaD
Flecainide—Vomiting—Doxorubicin—lung cancer	8.33e-05	0.000199	CcSEcCtD
Flecainide—SCN4A—Axon guidance—HRAS—lung cancer	8.33e-05	0.000798	CbGpPWpGaD
Flecainide—Rash—Doxorubicin—lung cancer	8.27e-05	0.000198	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—MMP2—lung cancer	8.26e-05	0.000791	CbGpPWpGaD
Flecainide—Dermatitis—Doxorubicin—lung cancer	8.26e-05	0.000197	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—MAP2K1—lung cancer	8.25e-05	0.00079	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—VEGFA—lung cancer	8.22e-05	0.000788	CbGpPWpGaD
Flecainide—Headache—Doxorubicin—lung cancer	8.21e-05	0.000196	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—STAT3—lung cancer	8.14e-05	0.00078	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—NRAS—lung cancer	8.12e-05	0.000778	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—SRC—lung cancer	8.02e-05	0.000768	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—IL6—lung cancer	7.97e-05	0.000764	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—VEGFA—lung cancer	7.81e-05	0.000748	CbGpPWpGaD
Flecainide—Nausea—Doxorubicin—lung cancer	7.79e-05	0.000186	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—MAPK3—lung cancer	7.78e-05	0.000745	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—NRAS—lung cancer	7.72e-05	0.000739	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—COL4A3BP—lung cancer	7.58e-05	0.000726	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—AZIN2—lung cancer	7.58e-05	0.000726	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—AZIN2—lung cancer	7.51e-05	0.00072	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—COL4A3BP—lung cancer	7.51e-05	0.00072	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—EGFR—lung cancer	7.4e-05	0.000709	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MAPK3—lung cancer	7.39e-05	0.000708	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—RAF1—lung cancer	7.31e-05	0.000701	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—ERBB2—lung cancer	7.24e-05	0.000693	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—EGFR—lung cancer	7.03e-05	0.000673	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	7.01e-05	0.000671	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KRAS—lung cancer	6.99e-05	0.00067	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	6.79e-05	0.00065	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—KRAS—lung cancer	6.64e-05	0.000636	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ATP5H—lung cancer	6.45e-05	0.000618	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—POMC—lung cancer	6.43e-05	0.000616	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ATP5H—lung cancer	6.39e-05	0.000612	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—POMC—lung cancer	6.37e-05	0.00061	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MMP9—lung cancer	6.21e-05	0.000595	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—HRAS—lung cancer	5.94e-05	0.000569	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—EP300—lung cancer	5.89e-05	0.000564	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	5.87e-05	0.000563	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PLBD1—lung cancer	5.74e-05	0.00055	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—SRC—lung cancer	5.72e-05	0.000548	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PLBD1—lung cancer	5.7e-05	0.000546	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—IL6—lung cancer	5.69e-05	0.000545	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—HRAS—lung cancer	5.64e-05	0.000541	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	5.6e-05	0.000537	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—VEGFA—lung cancer	5.57e-05	0.000534	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—STAT3—lung cancer	5.52e-05	0.000529	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—NRAS—lung cancer	5.51e-05	0.000527	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—IL6—lung cancer	5.4e-05	0.000518	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MAPK3—lung cancer	5.27e-05	0.000505	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HSD17B10—lung cancer	5.25e-05	0.000503	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—AKT1—lung cancer	5.25e-05	0.000503	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HSD17B10—lung cancer	5.21e-05	0.000499	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—EGFR—lung cancer	5.02e-05	0.000481	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CKB—lung cancer	4.88e-05	0.000468	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CKB—lung cancer	4.84e-05	0.000464	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KRAS—lung cancer	4.74e-05	0.000454	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTM2—lung cancer	4.59e-05	0.00044	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CNDP2—lung cancer	4.59e-05	0.00044	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTM2—lung cancer	4.55e-05	0.000436	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CNDP2—lung cancer	4.55e-05	0.000436	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—MTMR3—lung cancer	4.47e-05	0.000428	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—MTMR3—lung cancer	4.43e-05	0.000424	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PGAM1—lung cancer	4.35e-05	0.000417	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PGAM1—lung cancer	4.32e-05	0.000414	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP2A7—lung cancer	4.15e-05	0.000398	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP2A7—lung cancer	4.12e-05	0.000395	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SDC4—lung cancer	4.06e-05	0.000389	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SDC4—lung cancer	4.03e-05	0.000386	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—HRAS—lung cancer	4.03e-05	0.000386	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—IL6—lung cancer	3.86e-05	0.000369	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—RRM1—lung cancer	3.7e-05	0.000355	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTA3—lung cancer	3.7e-05	0.000355	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—RRM1—lung cancer	3.67e-05	0.000352	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTA3—lung cancer	3.67e-05	0.000352	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—AKT1—lung cancer	3.56e-05	0.000341	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—B4GALT5—lung cancer	3.48e-05	0.000333	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—B4GALT5—lung cancer	3.45e-05	0.000331	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTA4—lung cancer	3.39e-05	0.000324	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTA4—lung cancer	3.36e-05	0.000322	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTA2—lung cancer	3.3e-05	0.000316	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	3.28e-05	0.000314	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTA2—lung cancer	3.27e-05	0.000313	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTA1—lung cancer	3.18e-05	0.000305	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTA1—lung cancer	3.16e-05	0.000302	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ABCC3—lung cancer	3.15e-05	0.000302	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ABCC3—lung cancer	3.12e-05	0.000299	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—AKR1C1—lung cancer	3.05e-05	0.000292	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—AKR1C1—lung cancer	3.02e-05	0.00029	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—UGT1A1—lung cancer	2.96e-05	0.000284	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—UGT1A1—lung cancer	2.93e-05	0.000281	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GNG11—lung cancer	2.85e-05	0.000273	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GNG11—lung cancer	2.83e-05	0.000271	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—lung cancer	2.81e-05	0.00027	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALDOA—lung cancer	2.72e-05	0.00026	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALDOA—lung cancer	2.69e-05	0.000258	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NCOA3—lung cancer	2.64e-05	0.000253	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NCOA3—lung cancer	2.62e-05	0.000251	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	2.57e-05	0.000246	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ABCG2—lung cancer	2.57e-05	0.000246	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ADCY1—lung cancer	2.57e-05	0.000246	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ADCY1—lung cancer	2.54e-05	0.000244	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ABCG2—lung cancer	2.54e-05	0.000244	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ENO2—lung cancer	2.52e-05	0.000241	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HPGDS—lung cancer	2.52e-05	0.000241	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PPP2R1B—lung cancer	2.5e-05	0.00024	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HPGDS—lung cancer	2.49e-05	0.000239	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ENO2—lung cancer	2.49e-05	0.000239	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PPP2R1B—lung cancer	2.48e-05	0.000238	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	2.45e-05	0.000234	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTT1—lung cancer	2.44e-05	0.000234	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTT1—lung cancer	2.42e-05	0.000232	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GCLC—lung cancer	2.41e-05	0.000231	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP2A6—lung cancer	2.41e-05	0.000231	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP2A6—lung cancer	2.39e-05	0.000229	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GCLC—lung cancer	2.39e-05	0.000229	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	2.38e-05	0.000228	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ENO1—lung cancer	2.29e-05	0.000219	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ENO1—lung cancer	2.27e-05	0.000217	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.26e-05	0.000216	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.23e-05	0.000214	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP2E1—lung cancer	2.05e-05	0.000197	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP2E1—lung cancer	2.03e-05	0.000195	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NQO1—lung cancer	2.03e-05	0.000194	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NQO1—lung cancer	2.01e-05	0.000193	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.97e-05	0.000189	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.95e-05	0.000187	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—STK11—lung cancer	1.83e-05	0.000175	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—STK11—lung cancer	1.81e-05	0.000174	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.7e-05	0.000163	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTP1—lung cancer	1.69e-05	0.000162	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTP1—lung cancer	1.68e-05	0.000161	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CAT—lung cancer	1.65e-05	0.000158	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CAT—lung cancer	1.63e-05	0.000156	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.62e-05	0.000155	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ABCB1—lung cancer	1.6e-05	0.000153	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ABCB1—lung cancer	1.59e-05	0.000152	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—TYMS—lung cancer	1.57e-05	0.000151	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—TYMS—lung cancer	1.56e-05	0.000149	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTM1—lung cancer	1.55e-05	0.000149	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTM1—lung cancer	1.54e-05	0.000148	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP1A1—lung cancer	1.47e-05	0.000141	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ERCC2—lung cancer	1.46e-05	0.00014	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP1A1—lung cancer	1.46e-05	0.00014	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ERCC2—lung cancer	1.45e-05	0.000139	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—APOA1—lung cancer	1.26e-05	0.000121	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—APOA1—lung cancer	1.25e-05	0.00012	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.2e-05	0.000115	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CG—lung cancer	1.15e-05	0.000111	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CG—lung cancer	1.14e-05	0.00011	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—POMC—lung cancer	1.1e-05	0.000105	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—POMC—lung cancer	1.09e-05	0.000104	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CREBBP—lung cancer	1.07e-05	0.000103	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CREBBP—lung cancer	1.06e-05	0.000102	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CD—lung cancer	1.01e-05	9.72e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CD—lung cancer	1.01e-05	9.64e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALB—lung cancer	1e-05	9.6e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALB—lung cancer	9.93e-06	9.52e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CB—lung cancer	8.85e-06	8.47e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CB—lung cancer	8.77e-06	8.4e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTGS2—lung cancer	8.76e-06	8.4e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTGS2—lung cancer	8.69e-06	8.32e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTEN—lung cancer	7.64e-06	7.32e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTEN—lung cancer	7.58e-06	7.26e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—EP300—lung cancer	7.29e-06	6.98e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—EP300—lung cancer	7.23e-06	6.92e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CA—lung cancer	5.39e-06	5.17e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CA—lung cancer	5.35e-06	5.12e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—AKT1—lung cancer	4.41e-06	4.22e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—AKT1—lung cancer	4.37e-06	4.18e-05	CbGpPWpGaD
